Consistent with AMG’s Corporate Strategy, the company will continue to retain a portion of future earnings to improve the strength of its balance sheet and finance the development and expansion of its business. Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Investors | Corporate. Investor Relations Galapagos NV 0JXZ Morningstar Rating Rating as of Apr 13, 2022. Galapagos NV Galapagos NV ist auf die Erforschung und Entwicklung von Medikamenten spezialisiert, die auf neuartigen Targets basieren, die in menschlichen Primärzellen entdeckt und validiert wurden. Media: Carmen Vroonen Global Head Communications & Public Affairs +32 473 824 874. Investors: Elizabeth Goodwin. Mechelen, Belgium; 1 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Galapagos NV Galapagos announces planned retirement of CEO Journal of Crohn’s and Colitis (2013) 7, 322-337. Royal Bank of Canada lifted their price objective on [] We use cookies to help us improve your browsing experience and understand how people use our website. Yahoo. For any other matters not directly related to Investor Relations, please visit our company contacts page. Galapagos